ISCT 2021 | Automated manufacturing in cell and gene therapy

Delara Motlagh, PhD, MS, EMBA, Terumo Blood and Cell Technologies, Lakewood, CO, highlights the importance of automating complex manufacturing processes in cell and gene therapy (CGT) in order to reduce variability, mitigate process risks and improve consistency and reproducibility in the end product. Dr Motlagh describes the current landscape of manufacturing automation in CGT, as well as a range of automation technologies and solutions that are currently available, including the Spectra Optia system for therapeutic apheresis, the Quantum platform for cell expansion of multiple cell types and the Finia system, which allows automation of the fill and finish step. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.